---
document_datetime: 2023-09-21 17:34:34
document_pages: 2
document_pathfilename: www.ema.europa.eu/en/documents/steps-after-cutoff/xenical-epar-steps-taken-after-authorisation-when-cutoff-date-has-been-used_en.pdf
document_name: xenical-epar-steps-taken-after-authorisation-when-cutoff-date-has-been-used_en.pdf
version: success
processing_time: 0.524393
conversion_datetime: 2025-12-22 20:58:08.945146
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.64.1
  docling-core: 2.55.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
## STEPS TAKEN AFTER GRANTING THE MARKETING AUTHORISATION

For procedures finalised after 1 November 2003 please refer to module 8B .

- In accordance with Article 10(3) of Council Directive 92/27 EEC of 31 March 1992, the EMEA issued on 9 March 1999 a notification for amendment in the labelling text for the blister foil in all official languages. The respective Commission Decision was issued on 11 May 1999.
- On 6 November 1998 the Marketing Authorisation Holder (MAH) submitted an application for a type II variation relating to an update of section 4.5 of the SPC and the relevant section of the PL  concerning  the  interaction  of  Xenical  with  pravastatin.  The  CPMP  adopted  a  positive opinion on 27 January 1999. The respective Commission Decision was issued on 11 May 1999.
- On 27 November 1998 the MAH submitted an application for a type I variation relating to an additional  manufacturer  of  the  finished  product  in  Nutley,  New  Jersey,  USA.  The  procedure started on 17 December 1998. This variation was approved by the EMEA on 13 January 1999 and did not require any amendments to the Community Marketing Authorisation.
- On 20 January 1999 the MAH submitted an application for a type I variation relating to three additional  manufacturers  of  the  active  substance,  as  well  as  an  additional  milling  site  for  the active substance. A change in the address of the existing milling site is introduced as well. The procedure  started  on  1  February  1999.  This  variation  was  approved  by  the  EMEA  on  26 February 1999 and did not require any amendments to the Community Marketing Authorisation.
- On  5  March  1999  the  MAH  submitted  an  application  for  two  type  I  variations  relating  to modifications of the analytical methods for the active substance. The procedure started on 12 March 1999. These variations were approved by the EMEA on 13 May 1999 and did not require any amendments to the Community Marketing Authorisation.
- On 5 March 1999 the MAH submitted an application for a type I variation relating to a change to the visual control and weight control of the capsule. The procedure started on 12 March 1999. This  variation  was  approved  by  the  EMEA  on  31 March 1999  and  did  not  require  any amendments to the Community Marketing Authorisation.
- On  16  March  1999  the  MAH  submitted  an  application  for  a  type  I  variation  relating  to additional  packaging  sites.  The  procedure  started  on  19  March  1999.  This  variation  was approved  by  the  EMEA  on  16 April 1999  and  did  not  require  any  amendments  to  the Community Marketing Authorisation.
- On  15  April  1999  the  MAH  submitted  an  application  for  a  type  I  variation  relating  for  a modification of final step in the manufacture of the active substance. The procedure started on 21 April 1999. This variation was approved by the EMEA on 19 May 1999 and did not require any amendments to the Community Marketing Authorisation.
- On 23 April 1999 the MAH submitted an application for a type II variation to include additional information in the relevant parts of the SPC and PL with respect to hypersensitivity reactions reported  following  PSUR  1.  The  CPMP  adopted  a  positive  opinion  on  29  July  1999.  The respective Commission Decision was issued on 8 December 1999.
- On  19  October  1999  the  MAH  submitted  an  application  for  a  type  II  variation  to  include additional information in the relevant parts of the SPC and PL with respect to the concomitant administration of cyclosporin and fibrates with orlistat. The CPMP adopted a positive opinion on 19 January 1999. The respective Commission Decision was issued on 11 May 2000.
- On  29  September  2000,  the  MAH  submitted  applications  for  two  type  II  variations  in accordance with Article 6 of the Commission Regulation (EC) 542/95. The MAH applied for an update  of  the  section  4.5  of  the  SPC  and  PL  to  exclude  information  on  the  interaction  with biguanides based on a pharmacokinetic study, as well as an update of the section 4.8 of the SPC and PL to include information of hepatic disorders based on the PSUR 3. The CPMP adopted a

<div style=\"page-break-after: always\"></div>

positive  opinion  for  this  variation  on  26  January  2001.  The  respective  Commission  Decision was issued on 3 May 2001.

- On 12 October  2001  the  MAH  submitted  to  the  EMEA  applications  for  type  I  variations  in accordance with Article 4 of Commission Regulation (EC) No. 542/95, as amended. The scopes of the variations were to make a minor change of manufacturing process of the active substance and to change the test procedure for a starting material or intermediate used in the manufacture of the active substance. The procedure started on 13 December 2001. The EMEA notified the Commission  on  11  January  2002  that  the  variations  were  accepted  and  did  not  require  any amendments to the Community Marketing Authorisation.
- On 19 June 2001, the MAH submitted an application for a type II variation in accordance with Article 6 of Commission Regulation (EC) 542/95 as amended. The MAH applied for an update of sections 4.8 and 5.1 of the SPC to include information regarding the use of Xenical in obese and  overweight patients with type 2  diabetes.  The  CPMP adopted a positive opinion for  this variation on 21 March 2002. The respective Commission Decision was issued on 20 June 2002.
- On 10 September 2002, the MAH submitted an application for a type II variation in accordance with Article 6 of Commission Regulation (EC) 542/95 as amended. The MAH applied to update the SPC sections 4.4, 4.5 and 4.8 as requested by the CPMP following the assessment of the 5th Periodic Safety Update Report (PSUR). In addition, amendments were made to the section 4.9 considering  post-marketing  data  and  additions  to  section  4.5  resulting  from  completed  drugdrug  interaction  studies.  The  CPMP  adopted  a  positive  opinion  for  this  variation  on  21 November 2002. The respective Commission Decision was issued on 4 March 2003.
- On 10 March 2003, the MAH submitted an application for a type II variation in accordance with Article 6 of Commission Regulation (EC) 542/95 as amended. The MAH applied for changes to manufacture of the product. The procedure started  on 21 March 2003. The CPMP adopted a positive  opinion  for  this  variation  on  22  May  2003.  The  variation  did  not  require  any amendment to the Community Marketing Authorisation.
- On 16 April 2003, the MAH submitted an application for a type II variation in accordance with Article 6 of Commission Regulation (EC) 542/95 as amended. The MAH applied for an update of section 4.8 of the SPC to include two additional terms as requested by the CPMP following the assessment of PSUR 6. The PL was updated accordingly. The procedure started on 25 April 2003. The CPMP adopted a positive opinion for this variation on 26 June 2003. The respective Commission Decision was issued on 8 October 2003.
- For  the  first  renewal  of  Xenical,  the  CPMP  was  of  the  opinion  that  the  quality,  safety  and efficacy of this medicinal product continued to be adequately and sufficiently demonstrated and therefore considered that the benefit/risk profile continued to be favourable for the authorised indications and issued on 26 June 2003 a positive opinion for the renewal of the Community Marketing Authorisation. The respective Commission Decision was issued on 8 October 2003.